STAT

STAT, also known as Stat News, is a news platform focused on health topics that was launched on November 4, 2015, by John W. Henry, who also owns the Boston Globe. The site is produced by Boston Globe Media and is located in the Boston Globe's building. Rick Berke serves as the executive editor and has a background with both the New York Times and Politico. Kelsey Sutton from Politico described STAT as Henry's "most ambitious standalone site to date." By February 2016, the team comprised 45 employees.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#21558

United States

#4823

Health/Health

#104

Traffic sources

Monthly visitors

Articles

D.C Diagnosis: RFK Jr.'s vaccine advisers meet, CDC nominee grilled

1 day ago | statnews.com | John Wilkerson

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. After making a brief visit to the hospital due to feeling lightheaded, Senate Minority Leader Chuck Schumer (D-NY) gave this sage advice: drink some water and stay out of the heat.
GOP tax bill faces major setback as Senate parliamentarian strikes down key Medicaid measures

1 day ago | statnews.com | John Wilkerson |Daniel Payne

The Senate parliamentarian struck down several major health care measures in Republicans’ tax bill, including Medicaid changes that the GOP was counting on to help pay for President Trump’s tax cuts. The parliamentarian’s decision is a major challenge to Republicans’ plans to reap savings from the Medicaid program and could lead lawmakers to look for new savings across federal programs. It may make it more difficult for them to pass the bill ahead of Trump’s July 4 deadline.
Here's how Insmed grows to be the next $100 billion biotech

1 day ago | statnews.com | Adam Feuerstein

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Insmed CEO Will Lewis keeps a newspaper story from 2014 framed on the wall of his office. The headline reads, “Insmed joins the biotech trash heap.”If you’re wondering, I didn’t write that story, although I could have.
Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game

2 days ago | statnews.com | Elaine Chen

How did Novo Nordisk get to the position it’s in now — with its stock halved over the past year and the company widely seen as trailing Eli Lilly in the weight loss market it once led? “I’m not sure I fully accept the premise of the question,” Martin Lange, Novo’s head of development, responded. At the American Diabetes Association meeting in Chicago this week, Novo executives argued the company is not falling behind.
ACIP, the CDC vaccine advisory panel, will review long-approved immunizations

2 days ago | statnews.com | Jason Mast

A leader of a federal vaccine advisory committee said Wednesday that the panel would start a review of long-approved vaccines, as well as the cumulative effect of the shots given to children and adolescents. Martin Kulldorff, named co-chair of the Centers for Disease Control and Prevention’s vaccine advisory committee after health secretary Robert F.
FDA probes deaths of boys taking Sarepta Duchenne drug

2 days ago | statnews.com | Elaine Chen

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, I hope you’re able to stay cool wherever you are. Let’s get into the news today. • Viking Therapeutics announced the start of Phase 3 studies involving its injectable, GLP-1/GIP-targeted obesity drug, called VK2735.
Why the company behind a controversial medical device just pivoted — to bitcoin

2 days ago | statnews.com | Alex Hogan

In this week’s episode of a new video series from STAT, reporters Casey Ross and Lizzy Lawrence discuss their recent story on Semler Scientific, a medical device company that pivoted its focus to bitcoin speculation. The story is part of their ongoing investigative series into UnitedHealth Group, and it’s a pretty fascinating saga. Ross also discusses what it’s like to be the recipient of a confidential document that UnitedHealth inadvertently emailed to him during the reporting process.
Radical transparency at the FDA, and a pivotal moment for vaccines

3 days ago | statnews.com | John Wilkerson

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Health, faith-based, and anti-hunger organizations are undertaking a “relay fast” to protest Republicans’ budget reconciliation bill. That’s an interesting tactic in a town that runs on campaign donations and attack ads. As always, send tips to [email protected] or via Signal at John_Wilkerson.07.
Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options

3 days ago | statnews.com | Matthew Herper

The biotech firm Nuvalent said Tuesday that new data indicate its targeted drug zidesamtinib could help patients with a rare form of lung cancer that has failed other treatments. For 1% to 2% of patients with non-small cell lung cancer, tumors test positive for alterations in a gene called ROS1. ROS1-positive tumors often respond to one of five targeted therapies on the market, the first of which was approved in 2016 and the most recent of which was approved two weeks ago.
Balkanization of vaccine policy raises concerns about vaccine uptake, insurance coverage, experts warn

3 days ago | statnews.com | Helen Branswell

For decades, when health care providers in the United States made decisions about who among their patients should be vaccinated against which diseases and when, they knew where to look: the Centers for Disease Control and Prevention, which itself had been advised by a panel of independent experts, the Advisory Committee on Immunization Practices. Those days, at least for now, may be coming to an end.